<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679623</url>
  </required_header>
  <id_info>
    <org_study_id>RLM-559-01</org_study_id>
    <nct_id>NCT04679623</nct_id>
  </id_info>
  <brief_title>Study of Midazolam in Healthy Adults</brief_title>
  <official_title>Phase 1, Open-Label, Comparison Study to Evaluate the Safety and Pharmacokinetics of a Single Intramuscular Administration of 10 mg Midazolam Using an Auto-Injector vs Marketed Midazolam Vials in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rafa Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rafa Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1, open-label, crossover, comparison study to evaluate the safety and&#xD;
      pharmacokinetics (PK) of a single IM administration of 10 mg midazolam using Rafa's&#xD;
      auto-injector compared with seizalam in healthy adults. All subjects will participate in both&#xD;
      study periods which will span 28 days following a pre study screening visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2021</start_date>
  <completion_date type="Anticipated">July 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with local injection site changes</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with systemic changes in physical exam</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with vital signs changes resulting in a serious adverse event</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with ECG changes resulting in a serious adverse event</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with laboratory changes resulting in a serious adverse event</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to reach Cmax (Tmax) will be obtained directly from the plasma concentration-time profile data for each patient following IM injection</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The elimination rate constant (ke) will be estimated</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUC from time 0 to the time of the last measurable concentration (AUC0-last) and the AUC from time zero to infinite time (AUC0-∞)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability will be obtained by analysis of Cmax</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability will be obtained by analysis of AUC0-last</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability will be obtained by analysis of AUC0-∞</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>Midazolam Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam injection, 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seizalam™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seizalam, 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam Injection, 10mg</description>
    <arm_group_label>Midazolam Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seizalam</intervention_name>
    <description>Seizalam, 10 mg</description>
    <arm_group_label>Seizalam™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Can understand and provide signed informed consent&#xD;
&#xD;
          2. Is a healthy male or healthy, non-pregnant, non-lactating female whose screening,&#xD;
             physical exam, labs, vitals, and ECG are within normal range&#xD;
&#xD;
          3. Has a willingness to comply and be available for all protocol procedures&#xD;
&#xD;
          4. Is between age 18 and 55 years, inclusive on the day of injection&#xD;
&#xD;
          5. If the subject is female and of childbearing potential, she has a negative serum&#xD;
             pregnancy test at screening and negative urine test within 24 hours prior to injection&#xD;
             Note: A woman is considered of childbearing potential unless post-menopausal (≥ 1 year&#xD;
             without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy&#xD;
             or bilateral tubal ligation or successful Essure placement with documented&#xD;
             confirmation test at least 3 months after the procedure&#xD;
&#xD;
          6. If the subject is female and of childbearing potential, she agrees to practice&#xD;
             abstinence from sexual intercourse with men or use acceptable contraception up to 1&#xD;
             month after the end of study visit Note: Acceptable contraception methods are&#xD;
             restricted to effective devices (approved oral contraceptives, Intrauterine&#xD;
             Contraceptive Devices, NuvaRing®)&#xD;
&#xD;
          7. If the subject is male, he agrees to practice abstinence from sexual intercourse with&#xD;
             women or use acceptable contraception up to 1 month after the end of study visit&#xD;
&#xD;
          8. Has a body mass index (BMI) ≥18.0 and ≤26.0 kg/m2 at screening&#xD;
&#xD;
          9. Has a negative urine drug screen&#xD;
&#xD;
         10. Has a negative breathalyzer test&#xD;
&#xD;
         11. Subject is not taking any medications or St. John's wort and agrees to avoid&#xD;
             grapefruit juice and alcohol until study completion on Day 28&#xD;
&#xD;
         12. Subject agrees to not take any vitamins or supplements 48 hours prior to dosing&#xD;
&#xD;
         13. Is available for follow-up for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with another investigational drug within 28 days of initial dosing&#xD;
&#xD;
          2. Has a current or history of drug and /or alcohol abuse&#xD;
&#xD;
          3. Is pregnant or breastfeeding woman&#xD;
&#xD;
          4. Has hypersensitivity or allergy to midazolam&#xD;
&#xD;
          5. Has hypersensitivity or allergy to benzodiazepines&#xD;
&#xD;
          6. Has a history of cardiovascular, pulmonary, neurological, hepatic, renal, hematologic,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, or psychiatric disease or any&#xD;
             other reason, in the opinion of the investigator, that the patient should not&#xD;
             participate&#xD;
&#xD;
          7. Tests positive for HIV-1, HIV-2, HbsAg, hepatitis C antibody, or syphilis&#xD;
&#xD;
          8. Has had a blood donation in the 8 weeks prior to the study period start date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

